MedAdvisor’s ANZ Division Hits A$2.9M Revenue Amid Acquisition Interest

Strategic Options in Focus

MedAdvisor Limited (ASX: MDR), a global leader in pharmacy-driven patient engagement solutions, has taken a significant step in its ongoing strategic review by accepting a non-binding Letter of Intent (LOI) from a prominent multinational software company. The LOI proposes the acquisition of MedAdvisor's Australia and New Zealand (ANZ) business division for cash consideration, which the board believes represents a materially higher valuation than the current market price of MedAdvisor shares.

This development aligns with MedAdvisor's earlier announcements about exploring strategic initiatives to bridge the valuation gap between its market capitalisation and the board’s assessment of fair value for its ANZ and US operations. The ANZ business has demonstrated robust performance, achieving a record revenue of A$2.9 million in April 2025, underscoring its growth potential and attractiveness to buyers.

Details and Implications of the Offer

While the LOI remains non-binding and commercial terms are confidential, it includes customary conditions such as a period of exclusivity for due diligence. Both parties anticipate finalising a binding sale and purchase agreement within approximately 5 to 7 weeks. The identity of the prospective buyer has not been disclosed, but it is described as a multinational software business with operations in Australia, suggesting a strategic fit with MedAdvisor’s technology-driven platform.

MedAdvisor’s CEO, Rick Ratliff, expressed optimism about the offer, highlighting that it validates the strategic value of the ANZ business and signals confidence in its future growth. Importantly, the potential acquirer intends to continue investing in the business, which bodes well for the Australian pharmacy sector and the patients it serves.

Advisors and Next Steps

Adelaide Equity Partners Limited and HWL Ebsworth remain engaged to assist MedAdvisor with the strategic review and potential transaction. Investors will be watching closely as the due diligence process unfolds and as MedAdvisor provides further updates on the progress and any binding agreements.

While the LOI marks a promising milestone, the non-binding nature of the offer means there is no certainty the transaction will complete. Nonetheless, this move could reshape MedAdvisor’s strategic direction and unlock shareholder value if successfully executed.